Platelet Function in Ischaemic Heart Disease and Diabetes
Research type
Research Study
Full title
Haemostatic Function in Ischaemic Heart Disease and Diabetes Mellitus.
IRAS ID
251021
Contact name
Jonathan Gibbins
Contact email
Sponsor organisation
University of Reading
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Ischaemic heart disease (IHD) is a term used to describe problems associated with the narrowing of the coronary arteries due to atherosclerosis, which supply the myocardium with oxygenated blood. While this process is well established, we do not currently know the underlying mechanism of this process, particularly in relation to haemostatic function and platelet cell signalling and whether any haemostatic changes take place as a result of IHD. In this study, we will aim to examine haemostatic function using blood samples from patients with IHD using new technique assays.
Further to this, type 2 diabetes mellitus (T2DM) is a risk factor for IHD. We will therefore determine whether platelet function is modified in IHD and if so, whether changes are exacerbated in IHD patients who also have T2DM. Where modulation of platelet function is observed, we will initiate studies to understand the mechanistic basis of these observations. This study will allow us a greater understanding of haemostatic function in IHD and T2DM patients, and will impact on the development of safer and more effective drugs and treatment regimens for the management of IHD and T2DM.REC name
London - Hampstead Research Ethics Committee
REC reference
19/LO/0572
Date of REC Opinion
16 Apr 2019
REC opinion
Favourable Opinion